Ensysce Biosciences Announces Participation in Upcoming Investor Conferences

On November 16, 2026 Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an initial focus on CRPS (Complex Regional Pain Syndrome), reported that management of the recently acquired Cy Biopharma Inc., James Morrison, Chief Executive Officer; Roger Sawhney, MD, Chief Financial Officer and Chief Business Officer; and Prof. Richard Langford, Chief Medical Officer, will participate in two upcoming investor conferences:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The UBS Healthcare Therapeutics Conference

Format: Fireside chat

Date: Tuesday, November 17, 2026

Time: 2:40-3:10 p.m. GMT (9:40-10:10 a.m. ET)

Location: London, U.K.

The 38th Annual Piper Sandler Healthcare Conference

Format: Company presentation

Date: Thursday, December 3, 2026

Time: 2:10-2:30 p.m. ET

Location: New York, N.Y.

A live webcast of the UBS fireside chat can be accessed here.

(Press release, Ensysce Biosciences, NOV 16, 2026, View Source [SID1234674875])